ZS Pharma Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
200
- Latest Deal Type
-
M&A
- Financing Rounds
-
8
ZS Pharma General Information
Description
Operator of a biopharmaceutical company. The company is focused on the development and commercialization of highly selective, non-systemically absorbed therapeutics to treat renal, cardiovascular, liver and metabolic diseases. Its primary focus thus far has been development of sodium zirconium cyclosilicate (ZS-9), a highly selective inorganic cation exchanger designed to entrap excess potassium throughout the gastrointestinal tract. ZS-9 is being developed for the treatment of hyperkalemia, a potentially life-threatening condition characterized by abnormally high levels of potassium in the blood.
Contact Information
Website
www.zspharma.comCorporate Office
- 508 Wrangler Drive
- Suite 100
- Coppell, TX 75019
- United States
Corporate Office
- 508 Wrangler Drive
- Suite 100
- Coppell, TX 75019
- United States
ZS Pharma Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
ZS Pharma Comparisons
Industry
Financing
Details
ZS Pharma Competitors (11)
One of ZS Pharma’s 11 competitors is Phathom Pharmaceuticals, a Formerly VC-backed company based in Florham Park, NJ.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Phathom Pharmaceuticals | Formerly VC-backed | Florham Park, NJ | ||||
Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
Dermata | Formerly VC-backed | San Diego, CA | ||||
Regulus Therapeutics | Formerly VC-backed | San Diego, CA | ||||
Ardelyx | Formerly VC-backed | Fremont, CA |
ZS Pharma Patents
ZS Pharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20170151279-A1 | Extended use zirconium silicate compositions and methods of use thereof | Active | 14-Oct-2015 | ||
US-20190365800-A1 | Extended use zirconium silicate compositions and methods of use thereof | Active | 14-Oct-2015 | ||
AU-2016338753-A1 | Extended use zirconium silicate compositions and methods of use thereof | Active | 14-Oct-2015 | ||
AU-2016338753-C1 | Extended use zirconium silicate compositions and methods of use thereof | Active | 14-Oct-2015 | ||
US-9592253-B1 | Extended use zirconium silicate compositions and methods of use thereof | Active | 14-Oct-2015 | A61K33/24 |
ZS Pharma Signals
ZS Pharma Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
ZS Pharma FAQs
-
When was ZS Pharma founded?
ZS Pharma was founded in 2008.
-
Where is ZS Pharma headquartered?
ZS Pharma is headquartered in Coppell, TX.
-
What is the size of ZS Pharma?
ZS Pharma has 200 total employees.
-
What industry is ZS Pharma in?
ZS Pharma’s primary industry is Drug Discovery.
-
Is ZS Pharma a private or public company?
ZS Pharma is a Private company.
-
What is the current valuation of ZS Pharma?
The current valuation of ZS Pharma is
. -
What is ZS Pharma’s current revenue?
The current revenue for ZS Pharma is
. -
How much funding has ZS Pharma raised over time?
ZS Pharma has raised $403M.
-
Who are ZS Pharma’s investors?
503 Partners, Adage Capital Management, Alta Partners, Devon Park Bioventures, and Fidelity Investments are 5 of 14 investors who have invested in ZS Pharma.
-
Who are ZS Pharma’s competitors?
Phathom Pharmaceuticals, Sorrento Therapeutics, Dermata, Regulus Therapeutics, and Ardelyx are some of the 11 competitors of ZS Pharma.
-
When was ZS Pharma acquired?
ZS Pharma was acquired on 17-Dec-2015.
-
Who acquired ZS Pharma?
ZS Pharma was acquired by AstraZeneca.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »